PARP inhibition in castration-resistant prostate cancer

Future Oncol. 2016 Mar;12(5):577-80. doi: 10.2217/fon.16.1. Epub 2016 Jan 21.

Authors

Lucia Nappi¹, Martin E Gleave¹

Affiliation

¹ Vancouver Prostate Centre & Department of Urologic Science, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 26792387
DOI: 10.2217/fon.16.1

No abstract available

Keywords: DNA repair gene mutations; PARP inhibitors; castration-resistant prostate cancer; gene sequencing; targeted therapy.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Biomarkers
DNA Repair / genetics
Gene Expression Regulation, Neoplastic / drug effects
Germ-Line Mutation
Humans
Male
Molecular Targeted Therapy
Mutation
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / genetics
Prostatic Neoplasms, Castration-Resistant / metabolism
Signal Transduction / drug effects

Substances

Antineoplastic Agents
Biomarkers
Poly(ADP-ribose) Polymerase Inhibitors